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Abstract
Background: Narcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly
associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02. A sudden increase in the incidence of
childhood narcolepsy was observed after vaccination with AS03-adjuvanted Pandemrix influenza vaccine in Finland at the
beginning of 2010. Here, we analysed whether the coinciding influenza A H1N1pdm pandemic contributed, together with
the Pandemrix vaccination, to the increased incidence of childhood narcolepsy in 2010. The analysis was based on the
presence or absence of antibody response against non-structural protein 1 (NS1) from H1N1pdm09 virus, which was not a
component of Pandemrix vaccine.
Methods: Non-structural (NS) 1 proteins from recombinant influenza A/Udorn/72 (H3N2) and influenza A/Finland/554/09
(H1N1pdm09) viruses were purified and used in Western blot analysis to determine specific antibody responses in human
sera. The sera were obtained from 45 patients who fell ill with narcolepsy after vaccination with AS03-adjuvanted Pandemrix
at the end of 2009, and from controls.
Findings: Based on quantitative Western blot analysis, only two of the 45 (4.4%) Pandemrix-vaccinated narcoleptic patients
showed specific antibody response against the NS1 protein from the H1N1pdm09 virus, indicating past infection with the
H1N1pdm09 virus. Instead, paired serum samples from patients, who suffered from a laboratory confirmed H1N1pdm09
infection, showed high levels or diagnostic rises (96%) in H1N1pdm virus NS1-specific antibodies and very high cross-
reactivity to H3N2 subtype influenza A virus NS1 protein.
Conclusion: Based on our findings, it is unlikely that H1N1pdm09 virus infection contributed to a sudden increase in the
incidence of childhood narcolepsy observed in Finland in 2010 after AS03-adjuvanted Pandemrix vaccination.
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Introduction
Narcolepsy with cataplexy is characterised by an excessive
daytime sleepiness, cataplexy and disturbed nocturnal sleep. In
addition, patients may have other rapid eye movement (REM)
sleep-related symptoms such as hypnagogic hallucinations and
sleep paralysis [1]. A deficit in the endogenous hypocretin (orexin)
system due to neuronal destruction in the lateral hypothalamus is
considered to be the primary pathophysiological mechanism of the
disease in humans [2,3,4,5]. Most often narcolepsy starts between
12–25 years of age, while onset before the age of 10 has been rare
[6,7]. The peak mode of onset age is around 15 years [8]. It is
strongly associated with a genetic marker, human leukocyte
antigen (HLA) DQB1*06:02, indicating an autoimmune-mediated
process [9,10]. Seasonality of the onset and association of the
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disease with upper respiratory tract infections, including H1N1
[11] and/or streptococcal infections [12,13], suggest that infec-
tions could initiate or reactivate an immune response that leads to
the loss of hypocretin secreting cells and narcolepsy in genetically
susceptible individuals.
Previously, a 17-fold increase in the annual incidence of
narcolepsy, as compared to previous years in children aged under
17, was observed in Finland in 2010 [14]. When vaccinated and
unvaccinated children and adolescents were compared, about a
12-fold increase in the risk of narcolepsy was observed in
vaccinated individuals [15]. It was considered likely that
Pandemrix vaccination, perhaps together with other environmen-
tal factors, contributed to the increased incidence of narcolepsy in
HLA DQB1*06:02-positive children in Finland in 2010 [14,15].
More recently, an increased incidence of narcolepsy in Pandem-
rix-vaccinated children/adolescents was also observed in Sweden
and U.K. [16,17].
As the onset of narcolepsy has been shown to be seasonal, and
the cases of narcolepsy increased following the 2009 H1N1
pandemic in China [11], we wanted to analyse whether the
coinciding pandemic influenza A H1N1 infections contributed,
together with the AS03-adjuvanted Pandemrix vaccination, to the
sudden increase in the incidence of childhood narcolepsy that was
observed in Finland in 2010.
Methods
Ethical Permissions
The study protocol was reviewed and approved by the
Institutional Review Board of the National Institute for Health
and Welfare (THL), Helsinki. Children with narcolepsy diagnosed
after Pandemrix vaccination were recruited to the immunological
narcolepsy study at the neurological outpatient clinics in Finnish
children’s hospitals during the years 2011 and 2012. The study
protocol was approved by the Ethics Committee of participating
hospitals and informed written consent was given both by children
and their guardians.
The collection of serum samples from individuals suffering from
an upper respiratory tract infection was approved by the Ethical
Committee of the Pirkanmaa Hospital District (ETL-code
numbers R09152M and R10075M). All patients gave their written
informed consent for serum samples.
Control serum specimens for the study included serum samples
collected in 2004/2005 prior to the 2009 influenza pandemic. The
samples were made anonymous by destroying all person identi-
fication data before they were shipped to the National Institute for
Health and Welfare (THL); only the age of the subjects and the
sample collection dates were retained. Permission to use these
anonymous serum specimens was based on ethical permissions
given by the Helsinki-Uusimaa Health District Ethical committee:
HUS 315/E0/05 (dated 6.9.2005; initially for polio and MMR
antibody analyses) and 199/13/03/00/09 (dated on 30.6.2009;
expanded for influenza antibody analyses). The studies fully
comply with the rules concerning national and international
regulations, privacy and data protection relevant to medical- and
patient-oriented studies.
Identification of Narcoleptic Patients
The present study comprised 45 narcoleptic patients aged 5 to
18 years at onset who fell ill in 2009 or 2010 after receiving
Pandemrix vaccination in November or December 2009. The
description of the patients, their date of Pandemrix vaccination,
time of onset of narcolepsy and the time of serum sample
collection is shown in Table S1. The diagnosis of narcolepsy (ICD-
10 code G47.4) was based on the criteria of the International
Classification of Sleep Disorders (version 2, ICSD-2) [4]. A
Multiple Sleep Latency Test (MSLT) [1] and HLA DQB1 typing
with a panel of sequence specific oligonucleotide probes [18] were
carried out for all patients. Other causes of excessive daytime
sleepiness (EDS) (e.g. sleep apnea, delayed sleep phase syndrome
or sleep deprivation) as well as other neurological disorders
(encephalitis, encephalopathy, other neurological disorders) were
excluded by polysomnography, actigraphy, thorough neurological
examination, magnetic resonance imaging (MRI), electroenceph-
alography (EEG), cerebrospinal fluid (CSF) examinations, blood
tests, and other examinations when necessary. Based on the review
of patient records, an experienced neurologist and sleep specialist
(MP, TKirjavainen), independently of each other, validated the
time of onset and diagnosis of narcolepsy. If the opinion of the two
specialists differed significantly, the onset time and diagnosis was
verified by a panel of three neurologists/sleep specialists (alter-
nating CH, OSH, PO, SLH).
Serum Specimens from Narcoleptic Patients/Coupled
Paired Samples/Age-matched Controls
Serum specimens from all 45 narcoleptic patients were collected
during 2011. Paired serum specimens from 28 adults suffering
from a clinical, laboratory-confirmed H1N1pdm09 virus infection
were collected during the epidemic season 2009–2010 and 2010–
2011 in the Tampere city area. H1N1pdm09 infection was
confirmed by identifying viral RNA in nasopharyngeal stick
samples collected during the acute phase of the disease using a
diagnostic polymerase chain reaction (PCR) test with the NS gene
as the PCR target [19]. Five of the patients had previously been
vaccinated with Pandemrix.
Paired serum specimens were collected at the acute (at the time
of the diagnosis) and convalescent phases (14–21 days later) of the
disease. All patients showed a diagnostic antibody rise in the
H1N1pdm09 virus-specific hemagglutination inhibition assay (HI;
$4 6 rise; Table S3) or H1N1pdm09 NS1 protein-specific
Western blot assay ($26 rise; Table S3).
Control serum specimens from 50 randomly selected aged-
matched control individuals were collected from a larger serum
sample collection drawn in 2004 and 2005 (clearly prior to the
2009 pandemic) that was initially collected from diagnostic left-
over serum specimens from the HUSLAB (Helsinki, Finland)
diagnostic laboratory. Serum specimens were previously analysed
and they were found to be negative for anti-H1N1pdm09
antibodies as analysed by means of the hemagglutination
inhibition (HI) test [20] (Table S4).
Plasmids and DNA Manipulations
Regions coding for influenza A virus non-structural protein 1
(NS1) in the cDNAs for wild-type (wt) A/Udorn/72 (H3N2)
(Genebank accession number, V01102) and wt A/Finland/544/
09 (H1N1pdm09) (GQ283489.1) (NS) genes were modified by
PCR to create N- and C-terminal BamHI sites for further cloning
into an E. coli GST fusion vector pGEX-3X (Amersham
Biosciences, Buckinghamshire, UK). All DNA manipulations were
performed according to standard protocols, and the newly created
gene constructs were fully sequenced.
Production of Recombinant Glutathione-S-transferase
(GST)-NS1 Fusion Proteins in E. coli BL21 Cells, and
Purification of the Proteins
GST and chimeric GST-NS1 fusion proteins were expressed
under isopropyl-beta-thiogalactopyranoside (IPTG) induction in
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E. coli BL21 cells. For GST and GST-NS1 protein purification,
5 mg of sonicated, cellular protein samples in Laemmli sample
buffer [21] were subjected to preparative sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Model 491 Prep
Cell, Bio-Rad Laboratories). The recombinant GST and GST-
NS1 fusion proteins were separated on 12% and 7% gradient
SDS-PAGE gels, respectively [22].
Detection of NS1 Protein-specific Antibodies in Human
Sera by Western Blotting Using E. coli -expressed
Recombinant NS1 Proteins
To analyse humoral immune responses against NS1 proteins,
serum specimens were obtained from 45 narcoleptic patients.
Twenty eight paired serum samples were obtained from patients
who suffered from a laboratory confirmed H1N1pdm09 virus
infection, and 50 control sera were obtained from age-matched
children. For Western blot analysis, 3 mg of purified GST (26 kDa)
and GST-NS1 A/Udorn/72 (subtype H3N2, 52 kDa) or A/
Finland/544/09 (subtype H1N1pdm09, 52 kDa) proteins were
loaded on 12% SDS-PAGE gels. Proteins, separated on gels, were
stained with Coomassie Brilliant Blue or transferred onto
Immobilon-P membranes (polyvinylidine difluoride; Millipore)
with an Isophor electrotransfer device (Hoefer Scientific Instru-
ments, San Francisco, CA, USA). The membranes were sliced and
stained with serial dilutions of tested human sera (dilutions of
1:100, 1:1,000, 1:10,000, 1:100,000) in PBS, containing 5% nonfat
milk at room temperature for 2 h. After washing with PBS,
secondary peroxidase-conjugated anti-human IgG immunoglobu-
lins (Vector Laboratories, Burlingame, Inc., CA) were allowed to
bind at room temperature for 1 h. After washing with PBS, the
bands were visualised by 3-amino-9-ethylcarbazole (AEC) [23].
Western blot titers were determined as the last dilution showing a
positive result. If the staining was exceptionally strong in lower
dilution and negative in the next dilution the titer was determined
to be between the dilution factors.
Serological Hemagglutination Inhibition (HI) Test
Serum specimens, obtained from 45 narcoleptic patients, from
28 patients (56 paired serum specimens) suffering from influenza
infection and 50 age-matched control individuals, were analysed
by the HI test against influenza A/California/07/2009 vaccine
Figure 1. A phylogram of influenza A virus NS1 amino acid sequences from 113 human isolates representing strains circulating in
human population from 1918 to 2012. The phylogram was constructed by maximum parsimony method using MEGA 3.1 software. Branch
lengths represent number of amino acid changes as indicated by the scale bar. GenBank accession number and the generic name of the virus
subtype are shown. Viral NS1 sequences are grouped in different subtypes as indicated in the figure.
doi:10.1371/journal.pone.0068402.g001
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strain and epidemic A/Finland/814/01 (H1N1) and A/Finland/
715/00 (H3N2) virus strains isolated in Finland. The HI tests were
performed in accordance with World Health Organization
(WHO) guidelines with established procedures [24,25] using
turkey erythrocytes. Serum samples were pre-treated with receptor
destroying enzyme (RDE) from Vibrio cholerae filtrate (Denka
Seiken, Tokyo, Japan) at +37uC for 18 h followed by absorption
with 100% turkey erythrocytes at +4uC for one hour to remove
non-specific inhibitors and agglutinins. Serial 1:2 serum dilutions,
starting from 1:10 initial dilution, were performed. Then live viral
antigen (4 hemagglutinin (HA) units) was added and the samples
were incubated at ambient temperature for one hour. Turkey red
blood cells (0.5%) were added to antigen-serum solutions which
were then incubated at room temperature for 30 minutes to
determine the HI titers.
Statistical Analysis
Anti-NS1 titers in human sera were obtained by Western
blotting. These values were used for calculating the geometric
mean titers with 95% confidence intervals for each patient group.
The significances of the differences between the mean H1/H3
titers of narcoleptic patients and other patient groups were
calculated with Student’s t-test (two tailed, unequal variance).
Sequence Comparisons and Structural Analyses
To compare the genetic relationship of various human influenza
A virus NS1 proteins the sequences for N1N1pdm09, H1N1,
H2N2 and H3N2 virus NS1 genes were obtained from Genebank.
The software programme Mega version 4 [26] (Molecular
Evolutionary Genetics Analysis) was used for sequence compar-
isons of NS1 gene nucleotide and amino acid comparisons and for
the construction of the phylogenetic tree. The phylogenetic tree
was generated using the Neighbor-joining method [27] with the
maximum composite likelihood model [28]. Bootstrapping was
performed with 1000 duplicates [29].
Results
Pandemic Influenza A Virus Subtype H1N1pdm09 NS1
Protein Differs Considerably from the Seasonal H3N2 and
H1N1 Virus NS1 Proteins
In order to study whether the patients who developed
narcolepsy after Pandemrix vaccination in 2009–2010 were also
suffering from an H1N1pdm09 virus infection simultaneously or
after the vaccination, we carried out a computer search for
potential virus proteins that could form the basis for an
immunological distinction of vaccine or influenza infection-
induced immunity. Since the vaccine contained the H1N1pdm09
virus (A/California/7/2009) surface glycoproteins and internal
viral proteins from a vaccine backbone virus PR8 (A/Puerto Rico/
34 H1N1), it is not possible to distinguish vaccine or infection-
induced immunity by conventional immunological methods like
the HI test, the virus neutralization test or Western blotting against
viral structural proteins. However, since the Pandemrix vaccine
did not contain viral NS1 protein, which is abundantly produced
during virus infection, we analysed whether measuring an immune
response against the NS1 protein could serve as a method to
distinguish H1N1pdm09 virus infected and vaccinated individuals
from those that were only vaccinated.
First, we compared the amino acid homology of the NS1
proteins between the pandemic H1N1pdm09 viruses and the
pandemic/seasonal H1N1, H2N2 and H3N2 viruses to evaluate
the level of homology between different subtype NS1 proteins.
The NS genes of the 20th century human H1N1 and H3N2
influenza A viruses have evolved from the A/Brevig mission/18
virus [30]. The NS genes of the pandemic H1N1pdm viruses,
however, originate from classical swine influenza viruses [31] and
they are phylogenetically divergent from classical human influenza
A virus NS genes (Figure 1). As shown in Table 1, the amino acid
homology within the groups of seasonal H1N1 or H3N2 virus NS1
proteins is 88–98% and 90–100%, respectively. Also, the amino
acid homology of the influenza A virus Udorn/72 NS1 (H3N2)
protein, which is used in the present analysis, ranges between 84–
Table 1. Pairwise comparisons of the NS1 sequences of selected human influenza A viruses and vaccine virus strains.
Subtype Strain Sequence identity (%)
H1N1pdm09 H1N1 H3N2
Fin/
554/09
Cal/
7/09
USSR/
90/77
Sing./
6/86
New Cal./
20/99
Bris./
59/07
Udorn/
72
Bang./1/
79
Sich./
2/87
Mos./
10/99
Bris./
10/07
H1N1pdm09 Fin/554/09 100 75.5 74.7 78.7 75.7 73.4 72.6 73.0 74.8 74.8
Cal/7/09 100 75.5 74.7 78.7 75.7 73.4 72.6 73.0 74.8 74.8
H1N1 USSR/90/77 77.7 77.7 97.9 91.1 89.0 92.8 90.7 88.6 85.7 85.2
Sing./6/86 77.1 77.1 98.5 89.9 88.6 91.6 88.6 87.3 84.4 84.0
New Cal./
20/99
79.6 79.6 92.0 91.2 87.8 85.7 85.2 83.1 85.2 85.7
Bris./59/07 78.4 78.4 92.2 91.6 91.6 84.4 83.5 81.4 83.5 83.0
H3N2 Udorn/72 75.2 75.2 95.0 93.7 88.3 88.7 96.2 94.9 90.7 90.3
Bang./1/79 75.0 75.0 93.4 91.9 87.4 87.4 97.6 97.0 92.8 92.4
Sich./2/87 75.5 75.5 92.6 91.3 86.6 86.6 97.1 98.6 95.8 95.4
Mos./10/99 78.1 78.1 89.4 88.1 89.0 89.3 93.0 94.5 95.9 99.6
Bris./10/07 77.8 77.8 89.2 88.0 89.5 89.2 92.9 94.4 95.5 99.6
Figures in italic represent aligned NS1 nucleotide sequences and figures in boldface represent aligned NS1 amino acid sequences. All alignments were done using the
Needleman-Wunsch algorithm and the values indicate identity percentages. Full names of the strains are as follows: A/Finland/554/2009; A/California/07/2009; A/USSR/
90/77; A/Singapore/6/1986; A/New Caledonia/20/99; A/Brisbane/59/2007; A/Udorn/72; A/Bangkok/01/1979; A/Sichuan/02/87; A/Moscow/10/99; A/Brisbane/10/2007.
doi:10.1371/journal.pone.0068402.t001
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93% and 90–97%, as compared to seasonal H1N1 and H3N2
virus NS1 proteins, respectively (Table 1). In contrast, the amino
acid homology of the pandemic H1N1pdm09 NS1 protein is
clearly lower, ranging between 75–79% and 73–75% as compared
to H1N1 and H3N3 viruses, respectively. These differences may
be sufficient to distinguish infection-induced NS1 protein-specific
humoral immunity between seasonal and pandemic H1N1pdm09
influenza A virus infections.
Detection of NS1 Antibodies against Recombinant
Influenza A Virus NS1 Proteins in Human Sera
The analysis of narcoleptic patient sera and sera obtained from
H1N1pdm09 virus-infected individuals and controls was carried
out using purified recombinant influenza A/Udorn/72 (H3N2)
and influenza A/Finland/554/09 (H1N1pdm09) NS1 proteins by
Western blot technique. Western blot analysis was used since the
purification of NS1 protein in a native form is very difficult due to
its insolubility and stickiness. In addition, we had previously good
experience in analyzing specific antibody responses against
recombinant microbial proteins by Western blotting [32,33].
The method is highly specific and unlikely vulnerable to
nonspecific binding to impurities in antigen preparation seen e.g.
in the enzyme immune assay methods.
Serum specimens showed antibody reactivity against influenza
A virus NS1 proteins (GST-NS1 fusion protein) but hardly any
reactivity against the GST protein (Figure 2). All tested serum
specimens were positive for the H3N2 virus (Udorn/72) NS1
protein, while the reactivity against the H1N1pdm09 NS1 protein
was equal to or clearly lower than that of the Udorn NS1 protein
reactivity.
Sera from Narcoleptic Children and Adolescent Show
High Antibody Reactivity to the H3N2 Subtype Influenza
A Virus NS1 Protein but Low Reactivity to the
H1N1pdm09 Subtype Influenza A Virus NS1 Protein
Antibody titers against H1N1pdm09 subtype and H3N2
subtype influenza A virus NS1 proteins in serum specimens were
analysed from 45 narcoleptic patients (Figure 3, Tables S1, S2).
The NS1 protein proved to be highly immunogenic, since all
serum specimens were positive and showed high or relatively high
antibody levels against the H3N2 subtype influenza A virus NS1
protein. The serum reactivity against the H1N1pdm09 subtype
NS1 protein was generally very low and there were only two
individuals (Fig. 3, cases 2 and 27) whose anti-H1N1pdm09 NS1
protein-specific antibodies were equal to those seen against the
H3N2 virus NS1 protein. Antibody titers against H1N1pdm09
subtype and H3N2 subtype NS1 proteins ranged from ,100
(detection level was 1:100 of serum dilution) to 6000 and from 600
to 10,000, respectively. Geometric mean antibody titers against
H1N1pdm09 subtype and H3N2 subtype NS1 proteins in serum
specimens were 156 (95% CI, 111.4–218.6) and 2502 (95% CI,
1921.0–3257.9), respectively (Table 2).
Paired Serum Specimens from H1N1pdm09 Virus-
infected Patients Showed High Levels or a Diagnostic
Rise in Antibody Titers against the H1N1pdm09 Subtype
Influenza A Virus NS1 Protein and High Cross-reactivity
with the H3N2 Subtype NS1 Protein
In order to analyse whether clinical H1N1pdm09 infection leads
to the induction of NS1 protein-specific antibodies we analysed
paired serum samples from 28 laboratory confirmed influenza A
virus-infected patients. The samples had been collected during the
Figure 2. Analysis of NS1 protein-specific antibody responses in human sera by using recombinant influenza A virus NS1 proteins.
Three mg of E. coli-expressed and preparative SDS-PAGE -purified recombinant proteins was loaded onto 12% SDS-PAGE gels. GST (26 kDa) and GST-
NS1 A/Udorn/72 (H3N2) (52 kDa) proteins were loaded onto one gel and GST and GST-NS1 A/Finland/544/09 (H1N1) (52 kDa) proteins onto another
gel, respectively. Proteins separated on gels were transferred onto nylon membranes. The membranes were sliced and stained with serially diluted
human sera, obtained from five narcoleptic patients (patients: N001, N002, N003, N011, N014). In addition, paired serum samples were obtained from
three patients, who had suffered from a laboratory confirmed H1N1pdm09 virus infection (patients: 11/1;acute phase serum sample from patient 11),
11/2 (convalescent sample from patient 11), 15/1, 15/2, 25/1, 25/2), and five serum samples were obtained from age-matched, control individuals
(samples: 60, 79, 84, 86, 88), as indicated in the figure. The following dilutions were used: 1:100 (lane 1), 1:1,000 (lane 2) and 1:10,000 (lane 3). After
incubation with secondary Abs, the bands were visualized by staining with 3-amino-9-ethylcarbazole (AEC). GST and GST-NS1 proteins were
visualized by staining with Coomassie Brilliant Blue as shown on the left.
doi:10.1371/journal.pone.0068402.g002
Lack of Influenza in Pandemrix-Induced Narcolepsy
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e68402
1st and 2nd pandemic season in 2009/2010 and 2010/2011, when
the epidemic influenza A virus was almost solely of the
H1N1pdm09 subtype. Almost all (89%) patients who had suffered
from an H1N1pdm09 virus infection showed high or very high
levels (.600) or a significant rise (.2 x) in antibody titers against
the H1N1pdm09 subtype influenza A virus NS1 protein
(Figure 4A, Table S3). It is noteworthy that the H1N1pdm09
virus infection also induced NS1-specific responses that were
strongly cross-reactivity with the H3N2 subtype virus NS1 protein
(Figure 4B, Table S3). The rise in geometric mean titers was 15-
fold, from 551 (95% CI, 285.6–1063.4) to 8414 (95% CI, 4294.9–
16482.1), against the H1N1pdm09 subtype NS1 protein, and 7-
fold against the H3N2 subtype NS1 protein (from 1219 (95% CI,
721,6–2058,8) to 8536 (95% CI, 4454,4–16359,0)), respectively
(Table 2).
Control Sera from 50 Age-matched Children and
Adolescent Showed High Antibody Reactivity against the
H3N2 Subtype Influenza A Virus NS1 Protein but Low
Cross-reactivity to the H1N1pdm09 Subtype NS1 Protein
As an additional control, the antibody titers against the
H1N1pdm09 subtype and the H3N2 subtype influenza A virus
NS1 proteins were determined in serum specimens collected from
50 age-matched control children and adolescent (Table S4). The
serum specimens had been collected during the years 2004 and
2005, several years before the appearance of the pandemic
H1N1pdm09 virus. Also among these individuals NS1 protein
appeared to be highly immunogenic and all sera had antibodies
against the H3N2 subtype NS1 protein. Antibody titers against
H1N1pdm09 subtype and H3N2 subtype NS1 proteins ranged
from ,100 to 6000 and from 300 to 6000, respectively (Table S4).
Geometric mean antibody titers against H1N1pdm09 subtype and
H3N2 subtype NS1 proteins in serum specimens were 418 (95%
CI, 300.3–582.4) and 1637 (95% CI, 1313.6–2040.3), respectively
(Table 2). All specimens were negative for the pandemic
H1N1pdm09 virus as analysed by the HI test (Table S4). Among
these children the H3N2 infection had been far more frequent
than the seasonal H1N1 infection, since the seropositivity rate and
the GMT levels against seasonal H3N2 virus (86% seropositivity,
GMT 86) were clearly higher as compared to that of a seasonal
H1N1 virus (54% seropositivity, GMT 15) (Table S4).
A summary of anti-NS1 protein-specific GMTs and statistical
differences between the groups is shown in Table 2. Serum
specimens from narcoleptic patients showed highly significantly
lower anti-H1N1pdm09 NS1 protein antibody levels as compared
to those seen in virus-infected patients and control individuals
(Table 2). However, such differences were not observed in anti-
H3N2 NS1 protein-specific responses, with the exception of
convalescent serum specimens from H1N1pdm09 virus-infected
patients, who showed significant induction of cross-reactive
antibodies recognising also H3N2 virus NS1 protein (Table 2).
Figure 3. Column charts showing antibody titers against H1N1pdm09 subtype and H3N2 subtype influenza A virus NS1 proteins in
serum specimens obtained from narcoleptic patients. The relative antibody levels against N1N1pdm09 and H3N2 virus NS1 proteins were
determined as the last serum dilution showing a positive signal in Western blot analysis. Blue columns show antibody titers against H1N1pdm09
subtype, and yellow columns show antibody titers against H3N2 subtype influenza A virus NS1 proteins in serum specimens obtained from 45
narcoleptic patients. Sera 2 and 27 (red arrows) show equally high titer levels against both NS1 protein subtypes.
doi:10.1371/journal.pone.0068402.g003
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Discussion
Narcolepsy is considered as an immune-related disease, but the
precise mechanism of disease pathogenesis and etiology has
remained unresolved. Surprisingly, in 2010 in Sweden and
Finland it was observed that the incidence of childhood and
adolescent narcolepsy suddenly increased [14,15,16,34]. In both
countries this increase was observed several months after the
pandemic that peaked in October-November 2009 and the
national Pandemrix vaccination campaigns that took place
between October 2009 and February 2010. Increased incidence
of narcolepsy was subsequently observed in other European
countries as well [17]. The observations of the increased risk of
narcolepsy in vaccinated children and adolescents in comparison
to unvaccinated age-matched subjects suggested that AS03-
adjuvanted Pandemrix vaccination, perhaps together with other
environmental factors, contributed to the increased incidence of
narcolepsy in children in Finland in 2010 [15]. As the onset of
narcolepsy has been shown to be seasonal and the cases of
narcolepsy have increased following the 2009 H1N1 pandemic in
China [11], we wanted to analyse whether H1N1pdm09 virus
infection, together with the AS03-adjuvanted Pandemrix vaccina-
tion, contributed to the abrupt increase in the incidence of
childhood narcolepsy in Finland.
Han and co-workers found a 3-fold higher incidence of
narcolepsy following the 2009 H1N1pdm09 virus pandemic,
which appeared to be unrelated to influenza vaccination [11]. This
increased incidence of childhood narcolepsy decreased to baseline
within two years after the 2009 H1N1 pandemic, indicating that
the exceptionally high incidence of narcolepsy occurred only after
the winter of 2009–2010 [35]. Nohynek and co-workers found no
evidence of a change in the incidence of narcolepsy among
unvaccinated 4–19-year-olds after the first H1N1pdm09 epidemic
year in Finland, whereas a considerably increased (13-fold) risk
was associated with Pandemrix vaccination [15]. In the present
study, children/adolescents suffering from narcolepsy showed high
antibody levels to the H3N2 subtype influenza A virus NS1
protein but very low antibody levels to the H1N1pdm09 subtype
NS1 protein (Figures 2, 3, Table 2, Table S2). This was also the
case with age-matched control sera collected in 2004 and 2005
(Figure 2, Table 2, Table S3). Instead, patients who had suffered
from a pandemic H1N1pdm09 influenza virus infection showed
high antibody levels against the H1N1pdm09 subtype NS1 protein
and equally high cross-reactivity to the H3N2 subtype influenza A
virus NS1 protein (Figures 2, 4A, B, Table 2, Table S3). These
results strongly suggest that pandemic H1N1pdm09 influenza
virus infection was not the main contributing factor for the
increased incidence of narcolepsy in Finland in the beginning of
2010. In our analysis only 2 out of 45 narcoleptic patient sera
(4.4%) showed equally high antibody levels against H1N1pdm09
and H3N2 virus NS1 proteins, which provide indirect evidence
that H1N1pdm09 virus infection was not common among our
narcoleptic patients. In addition, clinical data from our patients
indicated that influenza-like illness (ILI) was found only in a
minority of our patients and other symptomatic upper respiratory
tract infection such as sore throat (streptococcal infection) were not
observed at all [14]. Our data, however, do not rule out the
possibility that infections such as influenza or streptococcal
infections could contribute to the onset of narcolepsy in children
and adolescent at the population level, but we did not find any
evidence of infections playing a significant role in our narcolepsy
patients. It also has to be pointed out that the nationwide
Infectious Disease Registry, which collects data on microbial
infections in Finland does not provide evidence that any of the 15
Table 2. Statistical analyses of serum specimens for each patient group.
Serum samples; n Geom. mean 95% confidence interval
anti-NS1
Narcoleptic patients H1pdm09 45 156.1 111.42218.6
Control patients H1pdm09 50 418.2 300.32582.4
Acute phase patient sera H1pdm09 28 551.1 285.621063.4
Convalescent phase patient sera H1pdm09 28 8413.6 4294.9216482.1
Narcoleptic patients H3 45 2501.7 1921.023257.9
Control patients H3 50 1637.1 1313.622040.3
Acute phase patient sera H3 28 1218.9 721.622058.8
Convalescent phase patient sera H3 28 8536.3 4454.4216359.0
Serum samples; Serum samples; p-value
anti-NS1 anti-NS1
Narcoleptic patients H1pdm vs. Control patients H1pdm ,0.001
vs. Acute phase patient sera H1pdm ,0.002
vs. Convalescent phase patient sera H1pdm ,0.001
Narcoleptic patients H3 vs. Control patients H3 0.018
vs. Acute phase patient sera H3 0.021
vs. Convalescent phase patient sera H3 ,0.002
Geometric mean antibody titers and 95% confidence interval against H1N1pdm09 subtype and H3N2 subtype NS1 proteins in serum specimens for each patient group.
Significance of the differences between the mean anti-NS1 H1/H3 virus protein antibody titers of narcoleptic patients and other patient groups.
Significance of the differences was calculated with Student’s t-test (two tailed, unequal variance).
doi:10.1371/journal.pone.0068402.t002
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Figure 4. Column charts showing acute and convalescent serum antibody titers against H1N1pdm09 subtype influenza A virus NS1
protein in serum specimens obtained from 28 patients who had suffered from pandemic H1N1pdm09 virus infection. A) Striped, light
blue columns show antibody titers against H1N1pdm09 subtype NS1 protein from acute phase serum specimens, and blue columns show
corresponding antibody titers from convalescent serum specimens in paired serum samples obtained from 28 patients who had suffered from
H1N1pdm09 influenza virus infection. All 28 patients had a laboratory confirmed infection as verified by positive results with viral M and NS RNA-
positive RT-PCR test. B) Blue columns show antibody titers against H1N1pdm09 subtype NS1 protein from convalescent serum specimens, and yellow
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000 confirmed H1N1pdm09 infection cases (all ages) diagnosed in
2009–2011 have developed narcolepsy.
Our findings [14,15] are supported by studies from Sweden and
U.K., which reported significant increase in the incidence of
narcolepsy with cataplexy in children vaccinated with Pandemrix
as compared to those in the same age group who were not
vaccinated [16,17,34]. Preliminary data from France, Norway and
Ireland also indicate a higher than expected number of narcolepsy
cases in children and adolescents after Pandemrix vaccination
[36,37,38], suggesting that in genetically susceptible children
Pandemrix vaccination may alone be sufficient to initiate/
accelerate narcolepsy.
The strongest genetic risk factor for narcolepsy is associated
with a specific HLA class II gene [9,10]. More than 90% of
patients with a cataplexic form of narcolepsy carry the HLA
DQB1*06:02 allele compared to a 27% frequency of the allele in
the general Finnish population. In the present study, all our
patients were positive for the HLA DQB1*06:02 allele showing a
very strong correlation of narcolepsy with this risk allele. Because
antibodies to NS1 protein were seen in 96% of controls with
confirmed H1N1 infection and about 27% have the HLA
DQB1*06:02 allele, the presence of HLA DQB1*06:02 allele in
the patients with narcolepsy seems not to be the explanation for
the lack of antibody response to the NS1 protein. Furthermore,
antibody responses to the H3 NS1 protein were seen in all our
narcolepsy patients.
Altogether, in Finland approximately 600 000 children and
adolescent were vaccinated with Pandemrix vaccine in 2009–2010
giving a theoretical figure of 150 000 children and teens with a
positive HLA DQB1*06:02 susceptibility gene to be at risk for
developing narcolepsy. At present, approximately 120 individuals
aged 5–18 have developed narcolepsy after the Pandemrix
vaccination campaign. This gives a prevalence figure of 80/100
000 vaccinated HLA DQB1*06:02 positive children. The figure is
high, but it also suggests that additional genetic and environmental
predisposing factors likely contribute to the onset of Pandemrix-
associated narcolepsy. At present, we are not aware of other
obvious predisposing factors apart from Pandemrix vaccination.
Presently, we do not know the mechanism by which the viral
antigen or the components of the AS03 adjuvant (squalene,
polysorbate80 or DL-alpha-tocopherol), and/or different excipi-
ents included in the suspensions could contribute to the induction
or enhancement of autoimmunity, leading to the onset of
symptomatic narcolepsy. Theoretically, it is possible that any
pro-inflammatory signal, whether it originates from a microbial
infection or vaccination, such as inflammation inducing Pandem-
rix vaccine, could trigger further development of autoimmunity by
a non-specific ‘‘bystander’’ mechanism, leading to clinical onset of
narcolepsy with cataplexy. We did not, however, find evidence for
influenza infection as a significant contributing factor in the
etiology of narcolepsy in our patients.
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